The modern world of pharmaceutical treatments would be unthinkable without vaccines. The good old story of how Edward Jenner in 1796 the observation that milk maids typically avoided smallpox because they had been exposed to the milder cowpox is really ‘engineering for a healthier world’ when it’s best.
It is a well-known truth that prevention is cheaper than treatment, and the whole vaccine business is a living example of what this may mean in real life. In fact, vaccines have helped prevent or even eradicate a number of serious diseases and this is an ongoing trend continuing in our modern world. New and promising vaccines are in development that may remove some of the human race’s biggest fears in life.
Today, the vaccine industry addresses a wealth of diseases, ranging from measles and flu through tropic diseases and paediatric vaccination programmes to cervical cancer, and is the fastest growing segment in the pharmaceutical industry.
In Africa and yet emerging economies, cancer vaccines or even flu vaccines are often a luxury. Short of HIV and malaria, both of which have yet no vaccine, emerging economies mainly require paediatric and similar vaccines. If these vaccines were used consistently, they could help eradicate illnesses like measles from the continent.
However, before this can happen, the price of the vaccines must be lowered and they must be available everywhere. At NNE Pharmaplan, we develop modular vaccine facilities, which will help facilitate this, by providing a cost-effective alternative to ’design to order’.